Enbrel and Humira Remain the Mainstay for First-Line Biologic Rheumatoid Arthritis Treatment

   Enbrel and Humira Remain the Mainstay for First-Line Biologic Rheumatoid
                             Arthritis Treatment

Over Half of Xeljanz-Treated RA Patients Were Biologic Naive at Initiation,
According to a New Report from BioTrends Research Group

PR Newswire

EXTON, Pa., Sept. 19, 2013

EXTON, Pa., Sept. 19, 2013 /PRNewswire/ --BioTrends Research Group, one of
the world's leading research and advisory firms for specialized
biopharmaceutical issues, finds that the vast majority of patients treated
with Amgen's Enbrel and AbbVie's Humira—significantly more patients than those
treated with any other nontraditional disease-modifying antirheumatic
drug—were biologic-naive and, therefore, taking these agents as their
first-line biologic treatment. Although Pfizer's Xeljanz has been on the
market for only about six months at the time this study was fielded, nearly 60
percent of rheumatoid arthritis (RA) patients currently treated with Xeljanz
were biologic-naive prior to initiation, which is in-line with its
FDA-approved label. Xeljanz-treated patients who were previously treated with
another agent were most commonly switched from Enbrel, Humira and
Bristol-Myers Squibb's Orencia IV.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The ChartTrends^®: Rheumatoid Arthritis (US) report also finds that, according
to rheumatologists managing their care, the majority of Xeljanz-treated RA
patients in the audit are showing good to excellent pain relief, functional
status and quality of life. Also, 81 percent of Xeljanz-treated RA patients in
the audit have experienced partial or complete remission since beginning
treatment.

"In addition to the positive response that physicians are reporting, nearly
three-quarters of Xeljanz-treated patients are showing no signs of progression
of structural damage," said BioTrends Research Group Associate Director Lynn
Price. "This is an important issue for Pfizer as they are seeking expansion of
the Xeljanz RA label to include inhibition of progression of structural
damage."

The recently published report also finds that treating rheumatologists would
consider switching over half of their patients who are currently treated with
Genentech's Actemra IV to the subcutaneous formulation of Actemra if it were
commercially available. Moreover, treating physicians would consider
switching 22-34 percent of their patients currently treated with Orencia IV
and 20-25 percent of their patients who are treated with Genentech/Biogen
Idec's Rituxan or Janssen Biotech's Simponi to subcutaneous Actemra,
Incyte/Eli Lilly's baricitinib, Sanofi/Regeneron's sarilumab or
GlaxoSmithKline/Janssen Biotech's sirukumab, if these agents were on the
market.

ChartTrends^®: Rheumatoid Arthritis (US) is a quantitative publication based
on patient audit data collected from 983 biologic- or Xeljanz-treated RA
patient charts provided by 217 rheumatologists in May - June 2013 in the
United States. Through an in-depth review of specific patient charts, details
such as product dosing and titration, switching, concomitant medications and a
host of laboratory and patient demographic variables help define patient types
and identify therapy triggers. Requirements for the patient charts include: at
least 18 years of age and less than 90 years of age, currently on one of the
FDA-approved biologic agents for RA or Xeljanz, and under the rheumatologist's
personal management for at least six months. All collection methods were
designed in compliance with HIPAA.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at www.bio-trends.com. BioTrends
is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.